MEDIA

Nanexa appoints new Chief Financial Officer

28 June, 2024
- Regulatory
Download attachment

Nanexa AB (publ) today announces that Cecilia Danckwardt-Lillieström will take over as Chief Financial Officer as of September 1, 2024, as the current CFO Björn Svanström has chosen to leave the company.

Cecilia has extensive experience from similar positions in the Life Science sector as well as senior roles in accounting and auditing. Cecilia holds a degree in Economics and Business Administration from Uppsala University.

"I welcome Cecilia to Nanexa and I am convinced that her expertise will contribute significantly to Nanexa's development and growth," says David Westberg, CEO of Nanexa. "I would also like to thank Björn Svanström for his excellent efforts during his time at Nanexa."

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com

The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

Nanexa appoints new Chief Financial Officer